Stefania Montemezzi1, Giuseppe Cardano2, Silvia Storer1, Nicolò Cardobi1, Carlo Cavedon3, Lucia Camera1. 1. Radiology Unit, Department of Pathology and Diagnostics, Azienda Ospedaliera Universitaria Integrata - Verona, P.le Stefani 1, 37126, Verona, Italy. 2. Radiology Unit, Department of Pathology and Diagnostics, Azienda Ospedaliera Universitaria Integrata - Verona, P.le Stefani 1, 37126, Verona, Italy. drpeppex@gmail.com. 3. Medical Physics Unit, Department of Pathology and Diagnostics, Azienda Ospedaliera Universitaria Integrata - Verona, P.le Stefani 1, 37126, Verona, Italy.
Abstract
OBJECTIVES: This study evaluated the feasibility of DWI for lesion targeting in MRI-guided breast biopsies. Furthermore, it assessed device positioning on DWI during biopsy procedures. METHODS: A total of 87 biopsy procedures (5/87 bilateral) consecutively performed between March 2019 and June 2020 were retrospectively reviewed: in these procedures, a preliminary DWI sequence (b = 1300 s/mm2) was acquired to assess lesion detectability. We included 64/87 procedures on lesions detectable at DWI; DWI sequences were added to the standard protocol to localize lesion and biopsy device and to assess the site marker correct positioning. RESULTS: Mass lesions ranged from 5 to 48 mm, with a mean size of 10.7 mm and a median size of 8 mm. Non-mass lesions ranged from 7 to 90 mm, with a mean size of 33.9 mm and a median size of 31 mm. Positioning of the coaxial system was confirmed on both T1-weighted and DWI sequences. At DWI, the biopsy needle was detectable in 62/64 (96.9%) cases; it was not visible in 2/64 (3.1%) cases. The site marker was always identified using T1-weighted imaging; a final DWI sequence was acquired in 44/64 cases (68.8%). In 42/44 cases (95.5%), the marker was recognizable at DWI. CONCLUSIONS: DWI can be used as a cost-effective, highly reliable technique for targeting both mass and non-mass lesions, with a minimum size of 5 mm, detectable at pre-procedural DWI. DWI is also a feasible technique to localize the biopsy device and to confirm the deployment of the site marker. KEY POINTS: • MRI-guided breast biopsy is performed in referral centers by an expert dedicated staff, based on prior MR imaging; contrast agent administration is usually needed for lesion targeting. • DWI represents a feasible, highly reliable technique for lesion targeting, avoiding contrast agent administration. • DWI allows a precise localization of both biopsy needle device and site marker.
OBJECTIVES: This study evaluated the feasibility of DWI for lesion targeting in MRI-guided breast biopsies. Furthermore, it assessed device positioning on DWI during biopsy procedures. METHODS: A total of 87 biopsy procedures (5/87 bilateral) consecutively performed between March 2019 and June 2020 were retrospectively reviewed: in these procedures, a preliminary DWI sequence (b = 1300 s/mm2) was acquired to assess lesion detectability. We included 64/87 procedures on lesions detectable at DWI; DWI sequences were added to the standard protocol to localize lesion and biopsy device and to assess the site marker correct positioning. RESULTS: Mass lesions ranged from 5 to 48 mm, with a mean size of 10.7 mm and a median size of 8 mm. Non-mass lesions ranged from 7 to 90 mm, with a mean size of 33.9 mm and a median size of 31 mm. Positioning of the coaxial system was confirmed on both T1-weighted and DWI sequences. At DWI, the biopsy needle was detectable in 62/64 (96.9%) cases; it was not visible in 2/64 (3.1%) cases. The site marker was always identified using T1-weighted imaging; a final DWI sequence was acquired in 44/64 cases (68.8%). In 42/44 cases (95.5%), the marker was recognizable at DWI. CONCLUSIONS: DWI can be used as a cost-effective, highly reliable technique for targeting both mass and non-mass lesions, with a minimum size of 5 mm, detectable at pre-procedural DWI. DWI is also a feasible technique to localize the biopsy device and to confirm the deployment of the site marker. KEY POINTS: • MRI-guided breast biopsy is performed in referral centers by an expert dedicated staff, based on prior MR imaging; contrast agent administration is usually needed for lesion targeting. • DWI represents a feasible, highly reliable technique for lesion targeting, avoiding contrast agent administration. • DWI allows a precise localization of both biopsy needle device and site marker.
Entities:
Keywords:
Biopsy; Breast; Diffusion magnetic resonance imaging; Feasibility studies; Magnetic resonance imaging
Authors: Nicky H G M Peters; Inne H M Borel Rinkes; Nicolaas P A Zuithoff; Willem P T M Mali; Karel G M Moons; Petra H M Peeters Journal: Radiology Date: 2007-11-16 Impact factor: 11.105
Authors: K Pinker; W Bogner; P Baltzer; S Trattnig; S Gruber; O Abeyakoon; M Bernathova; O Zaric; P Dubsky; Z Bago-Horvath; M Weber; D Leithner; T H Helbich Journal: Eur Radiol Date: 2013-12-05 Impact factor: 5.315
Authors: Katja Pinker; Linda Moy; Elizabeth J Sutton; Ritse M Mann; Michael Weber; Sunitha B Thakur; Maxine S Jochelson; Zsuzsanna Bago-Horvath; Elizabeth A Morris; Pascal At Baltzer; Thomas H Helbich Journal: Invest Radiol Date: 2018-10 Impact factor: 6.016
Authors: Laura Martincich; Matthieu Faivre-Pierret; Christian M Zechmann; Stefano Corcione; Harrie C M van den Bosch; Wei-Jun Peng; Antonella Petrillo; Katja C Siegmann; Johannes T Heverhagen; Pietro Panizza; Hans-Björn Gehl; Felix Diekmann; Federica Pediconi; Lin Ma; Fiona J Gilbert; Francesco Sardanelli; Paolo Belli; Marco Salvatore; Karl-Friedrich Kreitner; Claudia M Weiss; Chiara Zuiani Journal: Radiology Date: 2010-12-16 Impact factor: 11.105
Authors: Pascal Baltzer; Ritse M Mann; Mami Iima; Eric E Sigmund; Paola Clauser; Fiona J Gilbert; Laura Martincich; Savannah C Partridge; Andrew Patterson; Katja Pinker; Fabienne Thibault; Julia Camps-Herrero; Denis Le Bihan Journal: Eur Radiol Date: 2019-11-30 Impact factor: 5.315